Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenomics Studies in Acute Myeloid Leukemia disease progression

ABSTRACT: Epigenomics Studies in Acute Myeloid Leukemia disease progression

PROVIDER: PRJNA326264 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Epigenomics Studies in Acute Myeloid Leukemia disease progression [RNAseq]

Project description:We report the DNA methylation and transcriptional molecular features of paired diagnosis and relapsed Acute Myeloid Leukemia samples

2016-06-21 | GSE83533 | GEO

Epigenomics Studies in Acute Myeloid Leukemia disease progression [enhanced RRBS-seq]

Project description:We report the DNA methylation and transcriptional molecular features of paired diagnosis and relapsed Acute Myeloid Leukemia samples

2016-06-21 | GSE83532 | GEO

Epigenetic studies in Acute Myeloid Leukemia

Project description:Epigenetic studies in Acute Myeloid Leukemia

| PRJNA301478 | ENA

Dietary methionine starvation impairs acute myeloid leukemia progression

Project description:Dietary methionine starvation impairs acute myeloid leukemia progression

| PRJNA909277 | ENA

Epigenomics Studies in Acute Myeloid Leukemia disease progression

Project description:This SuperSeries is composed of the SubSeries listed below.

2016-06-21 | GSE83534 | GEO

Myeloid Leukemia

Project description:Myeloid Leukemia

| PRJNA941283 | ENA

Epigenomics studies in Acute Myeloid Leukemia (AML)

Project description:<p>Acute Myeloid Leukemia (AML) remains a clinical challenge since most patients diagnosed with AML will die from the disease. Some patients harbor treatment-refractory disease and others relapse with disease that in many cases is resistant to treatments. Our study was designed to understand the molecular basis of disease progression in AML through interrogation of patient samples collected through an international collaboration which assembled 138 paired (diagnosis and relapse) patient specimens.</p> <p>It is hoped that this resource will help researchers understand mechanisms of disease relapse in AML and contribute to the general pool of data available for analyses for this disease and general research use.</p>

| phs001027 | dbGaP

Gene expression changes associated with progression and response in chronic myeloid leukemia

Project description:Chronic myeloid leukemia (CML) is a hematopoetic stem cell disease with distinct biological and clinical features. The biological foundation of the stereotypical progression from chronic phase through accelerated phase to blast crisis is poorly understood. We used DNA microarrays to compare gene expression in 91 cases of CML in chronic (42 cases), accelerated (17 cases), and blast phases (32 cases). Three thousand genes were found to be significantly (p<10-10) associated with the progression from chronic to blast phase. A comparison of the gene signatures of chronic, accelerated, and blast phases suggest that the progression of chronic phase CML from chronic advanced phase (accelerated and blast crisis) CML is a two-step rather than a three-step process, with new gene expression changes occurring early in accelerated phase before the accumulation of increased leukemia blast cells. The genetic signature of advanced phase CML is similar to that of normal CD34+ cells; however, progression also involved novel genes not expressed in normal CD34+ cells. Especially noteworthy is deregulation of the WNT/b-catenin pathway, the decreased expression of both JunB and Fos, and dysregulation of genes under the control of MZF1 and delta EF1 zinc finger transcription factors. Studies of CML patients who relapsed after initially successful treatment with imatinib mesylate demonstrated a gene expression pattern closely related to advanced phase disease. Take together, these data suggest that CML progression begins relative early and before clinical and pathological detection, and features distinct genetic differences compared to normal hematpoetic cells that might provide diagnostic and therapeutic targets. Samples from different phases of CML were hybridized against the pool of chronic phases of samples.

2010-06-11 | E-GEOD-4170 | biostudies-arrayexpress

Homo sapiens

Project description:Epigenomics Studies in Acute Myeloid Leukemia disease progression [RNAseq]

| PRJNA326266 | ENA

Defective ribosome assembly impairs leukemia progression in a murine model of acute myeloid leukemia

Project description:Despite the advanced understanding of disease mechanisms, the current therapeutic regimens fail to cure most patients with acute myeloid leukemia (AML). In the present study, we address the role of protein synthesis control in AML leukemia stem cell (LSC) function and leukemia propagation. We apply a murine model of mixed-lineage leukemia-rearranged AML to demonstrate that LSCs synthesize more proteins per hour compared with the bulk of leukemia. Using a genetic model that permits inducible and graded regulation of ribosomal subunit joining, we show that defective ribosome assembly leads to a significant survival advantage by selectively eradicating LSCs but not normal hematopoietic stem and progenitor cells. Finally, transcriptomic and proteomic analyses identify a rare subset of LSCs with immature stem cell signature and high ribosome content that underlies the resistance to defective ribosome assembly. Collectively, our study unveils a critical requirement of high protein synthesis rate for LSC function, highlighting ribosome assembly as a therapeutic target in AML.

2024-10-08 | PXD038318 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data